Olema Pharmaceuticals (OLMA) Change in Account Payables (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Change in Account Payables of -$5.7 million for Q1 2026, down 31.84% year-over-year from -$8.3 million in Q1 2025, and down 198.41% quarter-over-quarter from $5.8 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Change in Account Payables (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Change in Account Payables data on file, last reported at -$5.7 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$5.7 million, down 31.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (up 147.74% YoY), and the FY2025 annual result was $4.6 million, up 83.19% from the prior year.
- Change in Account Payables retreated to -$5.7 million in Q1 2026 per OLMA's latest filing, from $5.8 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $5.8 million in Q4 2025 and troughed at -$5.7 million in Q1 2026.
- A 5-year average of $241294.1 and a median of $360000.0 in 2022 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables slumped 3060.0% in 2022, then soared 1514.98% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $360000.0 in 2022, then jumped by 36.39% to $491000.0 in 2023, then soared by 413.85% to $2.5 million in 2024, then surged by 128.81% to $5.8 million in 2025, then slumped by 198.41% to -$5.7 million in 2026.
- Business Quant data shows OLMA's Change in Account Payables at -$5.7 million in Q1 2026, $5.8 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | -5.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.68 Mn |
| Mar 31, 2026 | -5.68 Mn |
| Dec 31, 2025 | 5.77 Mn |
| Dec 31, 2025 | 5.77 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Sep 30, 2025 | 2.39 Mn |
| Jun 30, 2025 | 743,000.00 |
| Jun 30, 2025 | 743,000.00 |
| Mar 31, 2025 | -4.31 Mn |
| Mar 31, 2025 | -4.31 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | -1.67 Mn |
| Sep 30, 2024 | -1.67 Mn |
| Jun 30, 2024 | -3.30 Mn |
| Jun 30, 2024 | -3.30 Mn |
| Mar 31, 2024 | 4.96 Mn |
| Mar 31, 2024 | 4.96 Mn |
| Dec 31, 2023 | 491,000.00 |
| Dec 31, 2023 | 491,000.00 |